ESA Market Highlights Need For Follow-On Biologic Pathway – MedPAC

The lack of price competition for erythropoiesis-stimulating agents is one example of the need for a mechanism to approve biologic generics, the Medicare Payment Advisory Committee asserts in its March report to Congress